FDA transparency rebuffed in report

Share this article:
A minority staff report from the House Energy & Commerce Committee says FDA deputy commissioner Janet Woodcock and her successor as director of drugs Steven Galson had the lowest reporting rates of all agency officials required to report their meetings with industry and outside entities.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.